Home » Clinical laboratory » The lead vaccine candidate of Advaxis.

The lead vaccine candidate of Advaxis.

Advaxis reports 3-calendar year survival data from its ADXS11-001 Stage I trial for cervical cancer The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. Related StoriesNew findings reveal association between colorectal cancers and melanoma drug treatmentMeat-rich diet may boost kidney cancer riskStudy displays rare HER2 missense mutations do not spread breasts cancer on their own The patients experienced participated in the 1st human being trial of a live Listeria vaccine for the treatment of advanced, recurrent, metastatic cervix cancer in females who have failed prior cytotoxic treatment.Among the 888 sufferers, 1601 stenoses were qualified to receive PCI based on angiography, whereas 1304 stenoses were eligible for PCI on the basis of an FFR of 0.13 . Primary End Point At 24 months, at least one primary outcome event had occurred in 36 patients in the PCI group and in 86 sufferers in the medical-therapy group . In the registry group, at least one event in the primary end point occurred in 15 patients , with small difference between the PCI group and registry sufferers but a big difference between the medical-therapy group and registry individuals .